ConductScience.org, home
Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma
API referenceFor AI assistants

Trial · NCT03410693

Results by group20

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 20 of 20

Download this page as JSON
OutcomeGroupCategoryValueSpreadUnits
Objective Response Rate (ORR) - Central AssessmentRogaratinib (BAY1163877)_Overall Population19.595% Confidence Interval 11.8 to 29.4percentage of participants
Objective Response Rate (ORR) - Central AssessmentChemotherapy_Overall Population21.695% Confidence Interval 13.5 to 31.6percentage of participants
Objective Response Rate (ORR) - Central AssessmentRogaratinib_WT Population19.495% Confidence Interval 10.4 to 31.4percentage of participants
Objective Response Rate (ORR) - Central AssessmentChemotherapy_WT Population23.895% Confidence Interval 14.0 to 36.2percentage of participants
Disease-control Rate (DCR) - Central AssessmentRogaratinib (BAY1163877)_Overall Population50.695% Confidence Interval 39.6 to 61.5percentage of participants
Disease-control Rate (DCR) - Central AssessmentChemotherapy_Overall Population55.795% Confidence Interval 44.7 to 66.3percentage of participants
Disease-control Rate (DCR) - Central AssessmentRogaratinib_WT Population53.295% Confidence Interval 40.1 to 66.0percentage of participants
Disease-control Rate (DCR) - Central AssessmentChemotherapy_WT Population63.595% Confidence Interval 50.4 to 75.3percentage of participants
Progression-free Survival (PFS) - Central AssessmentRogaratinib (BAY1163877)_Overall Population2.795% Confidence Interval 1.6 to 4.6months
Progression-free Survival (PFS) - Central AssessmentChemotherapy_Overall Population3.295% Confidence Interval 2.7 to 4.4months
Progression-free Survival (PFS) - Central AssessmentRogaratinib_WT Population2.895% Confidence Interval 2.6 to 5.1months
Progression-free Survival (PFS) - Central AssessmentChemotherapy_WT Population4.095% Confidence Interval 2.8 to 6.1months
Duration of Response (DOR) - Central AssessmentRogaratinib (BAY1163877)_Overall Population4.995% Confidence Interval 2.2 to 7.0months
Duration of Response (DOR) - Central AssessmentChemotherapy_Overall Population5.895% Confidence Interval 3.5 to 7.7months
Duration of Response (DOR) - Central AssessmentRogaratinib_WT Population5.195% Confidence Interval 1.5 to 9.2months
Duration of Response (DOR) - Central AssessmentChemotherapy_WT Population7.095% Confidence Interval 2.7 to 8.4months
Number of Participants With Treatment Emergent Adverse EventsRogaratinib (BAY1163877)Any TEAE86Participants
Number of Participants With Treatment Emergent Adverse EventsChemotherapyAny TEAE82Participants
Number of Participants With Treatment Emergent Adverse EventsRogaratinib (BAY1163877)Any drug related TEAE81Participants
Number of Participants With Treatment Emergent Adverse EventsChemotherapyAny drug related TEAE76Participants

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03410693/results

API referenceFor AI assistants